Isosorbide dinitrate therapy reduced morbid events (7 per 85 patient-weeks vs 17 per 76 patient-weeks) and significantly increased maximal exercise duration compared to placebo.
RCT (n=16)
Double-blind
Crossover
Does isosorbide dinitrate reduce morbid events and improve symptoms in patients with severe congestive heart failure?
Isosorbide dinitrate reduced morbid events and improved symptoms and exercise duration in patients with severe congestive heart failure.
A randomized double-blind crossover trial included 16 patients with severe congestive heart failure who received isosorbide dinitrate or placebo for eight weeks, and then the opposite treatment for eight more weeks. All patients received their usual maintenance therapy with digitalis and diuretics. Seven morbid events occurred during 85 patient-weeks of isosorbide dinitrate therapy compared with 17 during 76 patient-weeks of placebo. Severity of congestive heart failure improved in all eight patients who received isosorbide dinitrate compared with two patients who showed improvement and five whose symptoms became worse with placebo. No significant differences in physical findings, cardiac dimensions, or resting hemodynamics were observed. Maximal exercise duration increased significantly by 2.54 minutes with isosorbide dinitrate therapy, and rose insignificantly by 1.24 minutes with placebo. This preliminary trial suggests that long-term vasodilator therapy may be clinically beneficial in congestive heart failure.
Joseph A. Franciosa (Fri,) conducted a rct in Severe congestive heart failure (n=16). Isosorbide dinitrate vs. Placebo was evaluated on Morbid events. Isosorbide dinitrate therapy reduced morbid events (7 per 85 patient-weeks vs 17 per 76 patient-weeks) and significantly increased maximal exercise duration compared to placebo.